Business context and reporting period
The filing is IsoRay, Inc.’s unaudited Form 10-Q for the quarter and six months ended December 31, 2016 (its fiscal second quarter), not a filing under the name Perspective Therapeutics, Inc. IsoRay manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. The company reported no revenue from its international distributors in the quarter.
Financial performance and liquidity
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 | Comparable 2015 period |
|---|---|---|---|
| Product sales | $1.028 | $2.109 | $1.189 / $2.450 |
| Gross profit (loss) | $(0.001) | $0.047 | $0.027 / $0.110 |
| Operating loss | $(1.479) | $(3.054) | $(1.410) / $(2.501) |
| Net loss | $(1.450) | $(2.947) | $(1.311) / $(2.331) |
| Loss per share | $(0.03) | $(0.05) | $(0.02) / $(0.04) |
Quarterly and six-month sales both declined 14% year over year. Gross margin was approximately negative 0.1% for the quarter and 2.2% for the six months, versus approximately 2.3% and 4.5%, respectively, in 2015. For the six months, research and development rose 59% to $0.322 million and sales and marketing rose 91% to $1.020 million; general and administrative expense fell 4% to $1.807 million.
Six-month operating cash use was $3.014 million, compared with $1.920 million in 2015. Investing used $0.448 million and financing used $0.009 million; cash and cash equivalents declined $3.471 million to $6.668 million. At December 31, cash plus certificates of deposit totaled $11.947 million; current assets were $13.179 million, current liabilities $0.871 million, working capital $12.373 million, and the current ratio 16.35. Total liabilities were $1.418 million; the filing reports no material borrowing debt.
Material changes versus the prior comparable period
- Lower sales reflected sales-account-manager turnover, key-account scheduling, and volatility in other brachytherapy applications. Prostate sales fell 14% in both the quarter and six-month period.
- Gross profit declined as sales fell, despite lower product costs from procurement savings, reduced depreciation and staffing, and process improvements.
- Operating expenses rose 3% for the quarter and 19% for the six months. Higher marketing, staffing, research activity, and rebranding costs were major factors.
- A $48,000 gain from revising the asset retirement obligation, following a production-facility lease extension, reduced reported operating expenses.
Outlook, risks, contingencies, and unusual items
- Management forecasts fiscal 2017 cash requirements approximately $0.8 million above the prior year, largely due to sales staffing and rebranding/marketing. It expects existing cash and certificates of deposit to cover operating needs for the remainder of fiscal 2017.
- Management’s fiscal 2017 target is 20% revenue growth. If achieved and sustained, and assuming no extraordinary expenses, management anticipates cash-flow break-even in three to five years; there is no assurance the growth target will be met.
- The company had invested approximately $190,000 in production automation through the quarter and expects to invest approximately $310,000 over the next 12 months. A new production facility remains conditional on obtaining financing.
- Failure to meet a Port of Benton property-development covenant is expected to require an estimated payment of approximately $256,000, subject to a final appraisal.
- A securities class action settlement for $3.5375 million was preliminarily approved and is to be paid by insurers, subject to final court approval scheduled for March 7, 2017. A related derivative action remains pending; the company may have to advance defense costs.
- Five customers represented approximately 48% of six-month revenue, with one customer representing approximately 23%. The filing identifies customer concentration and competition in prostate treatment as risks.
- The company extended its irradiation-services agreement with the University of Missouri through November 2021, subject to termination provisions, and extended its Cesium-131 purchase agreement through December 31, 2017.
- Management may seek equity, strategic collaborations, debt, or other financing; additional financing could be dilutive. Disclosure controls were reported effective, with no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for IsoRay, Inc., while the request metadata names Perspective Therapeutics, Inc.
- Track revenue trends, gross margin, and whether sales-team changes and marketing spending produce the targeted growth.
- Assess cash burn and funding needs against management’s stated liquidity outlook and planned automation and facility spending.
- Check final approval and insurer payment of the class-action settlement, developments in the derivative action, and the final Port of Benton appraisal/payment.
- Monitor dependence on a small customer group, availability of Cesium-131 supply, and potential dilution from future financing.